APACMed: Johnson & Johnson On Using ‘Big’ For Good In The COVID-19 Challenge
The crisis has seen companies reach deep for creative solutions
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.
You may also be interested in...
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Health care delivery has been transformed over the past decade, and so has Royal Philips, whose CEO Frans van Houten explains why both were necessary, and the extra impetus for system-wide change following the COVID-19 pandemic.
Fit For The Future: Industry Gets Involved As UK Medtech And Digital Health Care Regulation Reaches Turning Point
The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. That, and how the agency precisely will oversee UK device regulation in the future, are front of mind for industry.